Aims/hypothesis: Recent studies suggest that a circulating protein called TRAIL (TNF-related 24 apoptosis-inducing ligand) may have an important role in the treatment of type 2 diabetes. It has been 25 shown that TRAIL deficiency worsens diabetes and that TRAIL delivery, when it is given before 26 disease onset, slows down its development. This study aimed at evaluating whether TRAIL had the 27 potential not only to prevent, but also to treat type 2 diabetes.
Introduction
system (Life Technologies). Fluorescence for each cycle was quantitatively analyzed by StepOnePlus 176 real-time PCR system (Applied Biosystems). Gene expression was normalized to Rps9 or 18s. Results 177 are reported as ratio compared with the level of expression in untreated controls, which were given an 178 arbitrary value of 1. Primers are reported in Supplementary Table 1 . 179 In vitro studies on HepG2 cells and mouse primary hepatocytes 180 Human hepatocellular carcinoma cells (HepG2) obtained from ATCC were cultured in high glucose 181 DMEM, supplemented with 10% (v/v) fetal bovine serum, L-glutamine (2mM), penicillin (100U/mL), 182 and streptomycin (100 μg/mL) in a 5% CO2 atmosphere at 37°C. In order to mimic a high-fat diet 183 milieu, cells were grown in media supplemented with either BSA-conjugated palmitate (250 mM) or 184 BSA-conjugated oleate (250 mM). Cells were cultured for 24 hours with BSA-conjugated oleate with 185 or without TRAIL (1 ng/mL) for cell viability, lipid accumulation, and protein expression studies, 186 while they were cultured for 6 hours for gene expression analysis. Cell viability was assessed with the 187 MTT assay (Alfa Aesar; #L11939). Total intracellular lipid content was evaluated by Oil-Red-O 188 staining. Protein expression of PGC-1α was analyzed by immunofluorescence. Gene expression of 189 PPARγ, PGC-1α, and ATG7 was analyzed by RT-qPCR using the SYBR Green system (Life 190 Technologies). cDNA was synthesized as detailed for our in vivo analyses. Fluorescence for each cycle 191 was quantitatively analyzed by StepOnePlus real-time PCR system (Applied Biosystems). Gene 192 expression was normalized to GADPH or Rpl27, and reported as a ratio compared to the level of 193 expression in untreated controls, which were given an arbitrary value of 1. Primers are reported in 194 Supplementary Table 1 . 195 In addition, in parallel in vitro studies, mouse primary hepatocytes were isolated from C57BL/6J male 196 mice following a protocol adapted from Severgnini (17) . After digestion with collagenase IV, liver 197 suspension was passed through a cell strainer. Primary hepatocytes were washed 4 times and seeded on 198 11 pre-coated plates with a plating medium (Williams E Medium supplemented with CM3000, 199 ThermoFisher Scientific) for 5 hours in a 5% CO2 atmosphere at 37°C. Then, this medium was 200 changed to a maintenance solution (CM4000 ThermoFisher Scientific) for 24 hours before starting the 201 treatment. As before, primary hepatocytes were cultured for 24 hours with BSA-conjugated oleate 202 (250mM) or BSA alone, with or without TRAIL (1 ng/mL). Total intracellular lipid content was 203 evaluated by Oil-Red-O staining. Results are expressed as means ± standard error of the mean (SEM). Differences in the mean among 207 groups were analyzed using one-way or two-way ANOVA. Pairwise multiple comparisons were made 208 using Bonferroni post-hoc analysis. A threshold of p<0.05 was considered statistically significant.
209

Results
210
Animal model and in vivo bioavailability of TRAIL
211
Mice were put on a high-fat dietary regime to induce obesity and associated metabolic comorbidities 212 ( Figure 1A) . After 4 weeks, before drug randomization, HFD mice had increased in weight (6.3 ± 0.6 213 g) as compared to CNT mice (3.7 ± 0.6 g; p<0.05 vs HFD). HFD mice weighed 30.4 ± 0.5 g and CNT 214 mice weighed 28.9 ± 0.7 g. There were no differences between the groups in terms of fasting glucose 215 and insulin. Nevertheless, the glucose and insulin tolerance tests showed that HFD mice had developed 216 impaired glucose tolerance as compared to CNT mice (Figure 1B) . At this stage, HFD mice were 217 randomized to receive either TRAIL or saline by weekly IP injection for 8 weeks. This schedule was 218 chosen based on our previous study (7) . Mice tolerated this treatment well, and they did not show any 219 sign of distress during the study or gross abnormalities at necroscopic examination as compared to 220 those treated with saline, in line with previous reports (18). When we then looked at TRAIL 221 bioavailability, we found that TRAIL was detectable after 6 hours from the IP injection and then 222 disappeared 24 hours later. This data was in line with our imaging experiment showing that the highest 223 fluorescence signal of Cy5.5-TRAIL was detected 6 hours after the IP injection, and then tended to 226 At the end of the study, HFD mice became obese as compared to CNT mice. TRAIL treatment 227 significantly reduced body weight gain in HFD mice (Figure 2A) , without affecting their food and 228 energy intake. In particular, HFD mice ate 2.7 ± 0.2 g/day with an energy intake of 13.7 ± 1.2 229 Kcal/day, as compared to HFD+TRAIL mice, who ate 2.6 ± 0.3 g/day with an energy intake of 13.4 ± (Figure 2G-I) . Interestingly, TRAIL treatment was associated with a significant 238 increase in total cholesterol, driven by an increase in HDL cholesterol.
225
TRAIL treatment significantly reduced obesity, as well as adipose and systemic inflammation
239
TRAIL treatment significantly reduced impaired glucose tolerance. 240 The tolerance tests (Figure 3A-F) performed at the end of the study showed that the HFD resulted in 241 impairment of glucose clearance, leading to significant hyperglycemia and hyperinsulinemia 2 hours 242 after a glucose load (Figure 3D-E) . This was associated with the inability of insulin to lower glucose 243 levels to the levels of CNT mice (Figure 3F) . At fasting, glucose did not differ between the groups, 244 and HFD mice displayed only a significant hyperinsulinemia as compared to CNT mice (Figure 3G) , 245 indicating the presence of an insulin resistance with impaired glucose tolerance. This data was 246 consistent with the lack of significant changes in β-cell mass and density ( To understand why TRAIL reduced impaired glucose tolerance, we looked at the tissues regulating 251 glucose metabolism, focusing on the liver and skeletal muscle (22) . At the end of the study, the HFD 252 regime did not increase the deposition of fat (lipid droplets) in the skeletal muscle, as assessed by Oil-
Red-O staining (data not shown). By contrast, when we looked at the liver, HFD mice developed 254 significant steatosis (lipid accumulation >10% of tissue area), which was assessed by Oil-Red-O 255 staining and by TG content quantification (Figure 4 A-C) . The accumulation of more than 5-10% of 256 fat in the liver, without any primary cause such as viral hepatitis, alcoholic disease, or drug-induced 257 liver injury is what defines histologically non-alcoholic fatty liver disease (NAFLD) (23). In our study, 258 HFD mice also exhibited a significant increase in liver macrophage infiltration (Figure 4C-D) , but no 259 fibrosis, which should appear after about 50 weeks of HFD (12). TRAIL treatment significantly 260 reduced liver steatosis as well as inflammation, therefore ameliorating HFD-induced NAFLD.
261
TRAIL significantly increased PGC-1α expression in the liver 262 In parallel studies, we quantitated liver mRNA encoding transcription factors and metabolic enzymes 263 involved in de novo lipogenesis, fatty acid oxidation, glucose metabolism, and mitochondrial function, 264 as well as pro-oxidative and proinflammatory molecules. In the liver, HFD significantly increased the 265 gene expression of Fas, Pparγ, and Il-6, while it decreased that of Cpt1α, Pepck, and Pgc-1α, as 266 compared to CNT mice ( Table 1) . In HFD mice, TRAIL significantly decreased the gene expression of 267 Fas and Il-6, while it increased that of Pparγ and Pgc-1α (Table 1; Figure 4E-F) . The increase in 268 Pparγ and Pgc-1α gene expression that followed TRAIL treatment was observed only in the liver 269 ( Supplementary Figure 2A) . Given that PGC-1α regulates energy metabolism and could explain part 270 of our findings, we further evaluated it by immunostaining. In HFD mice, PGC-1α protein expression 271 increased and changed pattern of distribution as compared to CNT mice, where it was located in the 272 nuclei. TRAIL further increased PGC-1α protein expression in the liver (Figure 4C and Figure 4G) . 273 In addition, we quantitated liver mRNA encoding for Atg7, which is a protein essential for autophagy, a 274 process that has been recently implicated in lipid metabolism regulation (24). Interestingly, an increase 275 in Atg7 was observed in the liver of HFD+TRAIL mice (Table 1; Supplementary Figure 2A To determine whether TRAIL had direct effects on hepatocytes, we used an in vitro model of NAFLD 279 (9), and cultured HepG2 cells with either palmitate or oleate. It must be noted that, although HepG2 280 cells are derived from liver hepatocellular carcinoma and they express TRAIL receptors 281 ( Supplementary Figure 2B) , they are normally resistant to TRAIL-induced apoptosis (25). MTT assay 282 showed that palmitate significantly impaired HepG2 cell viability, while oleic acid had no effect on it 283 (Figure 5A) . In HepG2 cells cultured with oleic acid, TRAIL treatment promoted cell viability ( Figure   284 5A), which is consistent with earlier observations that TRAIL can also activate survival pathways (26).
285
Most importantly, in these cells, TRAIL treatment reduced lipid droplet accumulation by 45% ( Figure   286 5B-C). This effect was confirmed in primary hepatocytes, where TRAIL treatment reduced lipid 287 droplet accumulation by 39% (Figure 5B-C) . In addition, in HepG2 cells cultured with oleic acid, 288 TRAIL upregulated PPARγ, PGC-1α, and ATG7 gene expression (Figure 6A-C) , as well as PGC-1α 289 protein expression (Figure 6D) , while it had no effect on specific proinflammatory markers 290 (Supplementary Figure 2C) . The first new finding of this study is that TRAIL significantly ameliorated diet-induced metabolic 294 abnormalities even when it was administered after the development of impaired glucose tolerance. At 295 the end of the study, HFD mice became obese and insulin resistant, displaying impaired glucose 296 tolerance as well as an increase in NEFA and CRP levels. By comparison, the group of HFD+TRAIL 297 mice showed a significant reduction in body weight gain, NEFA and CRP levels, as well as a 298 significant amelioration of insulin resistance and impaired glucose tolerance.
299
Looking at the adipose tissue, TRAIL reduced body weight gain, which was associated with a decrease 300 in fat weight, adipocyte size, and pgWAT macrophage infiltration. These findings are consistent with 301 the earlier observations that TRAIL had significant effects on body weight. As a matter of fact, genetic 302 TRAIL deficiency was found to be associated with increased body weight (8), and we reported that 303 TRAIL treatment significantly reduced the adiposity of HFD-fed mice as assessed by EchoMRI (7).
304
More recently, it has been shown that TRAIL has the ability to inhibit adipogenic differentiation 305 through caspase activation (27) . When interpreting our results in light of this finding, it is also by 306 reducing fat mass that TRAIL could have ameliorated insulin resistance, impaired glucose tolerance, as 307 well as circulating NEFA and CRP in HFD mice. Excess fat mass has been associated not only with 308 insulin resistance (20), but also with high levels of NEFA (20) and a low-grade systemic inflammatory 309 state (21). Moreover, experimental studies have shown that insulin sensitivity and systemic 310 inflammation improve following adipose tissue removal (28).
311
In this study, HFD mice developed also hepatic steatosis and inflammation, corresponding to human 312 non-alcoholic fatty liver disease (NAFLD). At present, NAFLD is found to be a frequent comorbid 313 factor in the setting of type 2 diabetes (29, 30) . It is estimated that about 70% of obese patients with 314 diabetes have NAFLD and as many as 30-40% have non-alcoholic steatohepatitis (NASH), which is 315 characterized by hepatic steatosis with inflammation and/or necrosis (30). Both NAFLD and NASH are 316 conditions leading to hepatic cirrhosis, end-stage liver disease, and hepatocellular carcinoma (29).
317
Given that NAFLD is reaching epidemic proportions in diabetic patients (29, 30) , it is predicted that 318 cirrhosis related to NASH will surpass HCV-related cirrhosis as the most common indication for liver 319 transplantation in the United States (31).
320
Therefore, the second important finding of this study is that TRAIL treatment markedly reduced 321 NAFLD in the HFD-fed mouse, where it decreased liver fat content by 47%. Given that NAFLD 322 generally promotes metabolic abnormalities (29, 30) , it is also by reducing liver fat content that TRAIL 323 might have ameliorated insulin resistance and subclinical inflammation in HFD-fed mice. To date, only 324 a few studies have addressed the relationship between TRAIL and NAFLD (9, 32). By comparison, this 325 is the first study describing the direct effect of TRAIL in an experimental model of NAFLD.
326
Nevertheless, our data is consistent with the finding that TRAIL deficiency worsens NAFLD (9).
327
There seem to be several mechanisms underlying TRAIL actions on the liver. First, the reduction in 328 body weight gain, fat mass, and circulating NEFA, which were induced by TRAIL, could have 329 ameliorated NAFLD in the HFD+TRAIL group. It has been argued that excess storage of hepatic 330 triglycerides comes mostly from an excess of circulating NEFA (33), which is usually associated with 331 visceral obesity (34) or adipose tissue insulin resistance/inflammation (34, 35) . Second, the significant 332 reduction of insulin, which was observed in the HFD+TRAIL group, could have also contributed to 333 NAFLD amelioration. Hyperinsulinemia usually contributes to liver steatosis. Insulin promotes the 334 synthesis and inhibits the degradation of lipids (36). It stimulates key lipogenic genes in the liver, such 335 as fatty acid synthase (FAS), while reducing CPT1, which is the transporter of NEFA into 336 mitochondria, thereby reducing fatty acid oxidation (36). FAS inhibitors have proven useful to reduce 337 liver triglyceride content (37). In this study, HFD mice displayed an upregulation of Fas and a 338 downregulation of Cpt1a in the liver. TRAIL significantly reduced HFD-induced Fas upregulation, 339 consistent with the reduction of insulin and liver steatosis. Third, this study clearly shows that TRAIL 340 also has direct actions on hepatocytes, where it significantly decreased fat content.
341
In this study, TRAIL significantly reduced lipid droplet accumulation in both HepG2 cells and primary 342 hepatocytes cultured with oleate. Our results are consistent with the observation that TRAIL treatment 343 reduces palmitate-induced lipid uptake by 30% in hepatocytes (9). Interestingly, in this study, TRAIL 344 promoted hepatocyte cell viability and did not have anti-inflammatory effects in vitro, suggesting that 345 the in vivo reduction of liver inflammation might be secondary to the amelioration of steatosis. In Moreover, PGC-1α seems to have a suppressive effect on liver inflammation (49). Therefore, our 360 results suggest that TRAIL effects on the liver and glucose metabolism might involve PPARγ and/or 361 PGC-1α actions.
362
In addition, based on our in vitro studies, where TRAIL increased ATG7, a possible unifying 363 hypothesis explaining TRAIL effects on liver steatosis and PGC-1α is that they might be due to 364 TRAIL-induced liver autophagy (50). Autophagy is a mechanism by which TG content, lipid droplet 365 number and size is regulated. In this process, lipids are sequestered in autophagosomes where they are 366 degraded (24). This should stimulate mitochondrial β-oxidation (24). Moreover, autophagy seems to 367 regulate the flux of cholesterol out of the cell to APOA-I (51), which is the major component of HDL 368 and could explain the increase in HDL cholesterol that we found in HFD+TRAIL mice. Further studies 369 are needed to evaluate the mechanisms underlying TRAIL effect on liver steatosis and PGC-1α, as well 370 as to test in detail the hypothesis that they might include TRAIL actions on liver autophagy.
371
In conclusion, this study shows that TRAIL was effective in reducing HFD-induced metabolic 372 abnormalities even when it was administered after the development of impaired glucose tolerance.
373
Second, this study shows that TRAIL markedly improved NAFLD in HFD-fed mice, and that this was 374 associated with a significant increase in PGC-1α. Overall, our results shed light on the therapeutic 375 potential of TRAIL against diabetes, NAFLD, and NASH. Experimental evidence suggests that a circulating protein called TRAIL protects against type 2 379 diabetes. This study was designed to evaluate whether TRAIL had the potential not only to 380 prevent, but also to treat diet-induced type 2 diabetes.
381
Our in vivo results show that TRAIL had the ability to attenuate the metabolic abnormalities 382 induced by a high-fat diet, also when TRAIL was given after disease onset (after 4 weeks of 383 high-fat diet). In particular, TRAIL treatment significantly reduced body weight, impaired 384 glucose tolerance, and liver steatosis, all of which are frequently associated with type 2 385 diabetes.
386
Our in vitro results show that TRAIL has direct effects on hepatocytes, where it reduces lipid 387 droplet accumulation. This data sheds light on TRAIL therapeutic potential against impaired 388 glucose tolerance and NAFLD. 
